T/O should be rejected at every opportunity as it's too opportunistic.
Analysts keep missing one thing about the company that is 10% of revenue goes towards product development. They pivoted on that early last year - if there was no product development then EBITDA would obviously be higher.
The US$186m revenue attributed to EBITDA at US$9.6m loss - if you subtract product development costs thats a ~US$9m gain and 50%+ from 1H FY21.
What I am trying to say is - T/O needs to be fair to reflect the business and cash generation capabilities. Nasdaq just had a historical smashing and revenue decrease of 7% is due to the macro environment with interest rates and Big Tech cutting back on spending due to uncertainty.
T/O should be rejected
Ann: 2022 Half Year Results & FY2022 Outlook, page-62
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add APX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.025(5.00%) |
Mkt cap ! $105.9M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 50.5¢ | 47.0¢ | $1.575M | 3.286M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56376 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 10207 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| APX (ASX) Chart |